Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer.
10.3802/jgo.2009.20.3.151
- Author:
Yong Wook JUNG
1
;
San Hui LEE
;
Ji Heum PAEK
;
Eun Ji NAM
;
Sang Wun KIM
;
Jae Hoon KIM
;
Jae Wook KIM
;
Young Tae KIM
Author Information
1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women's Cancer Clinic, Yonsei University College of Medicine, Seoul, Korea. ytkchoi@yuhs.ac
- Publication Type:Original Article
- Keywords:
Cervical cancer;
Efficacy;
Toxicity;
Rofecoxib;
Chemoradiotherapy
- MeSH:
Chemoradiotherapy;
Cyclooxygenase 2;
Humans;
Lactones;
Medical Records;
Neutropenia;
Retrospective Studies;
Sulfones;
Treatment Failure;
Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology
2009;20(3):151-157
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy (CCRT) in patients with cervical cancer. METHODS: We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who received CCRT only (N=37). The patients' medical records were retrospectively reviewed for patient characteristics, toxicity related to CCRT and treatment results. RESULTS: There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) patients experienced treatment failure. Progression-free and overall survival was 55.8+/-4.2 and 59.0+/-2.8 months, respectively, in the study group, and 69.7+/-4.3 and 71.6+/-3.6 months, respectively, in the control group. There were no differences in progression-free and overall survival between the 2 groups. CONCLUSION: Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study.
